The EHA Research Roadmap: Malignant Lymphoid Diseases

Martin Dreyling; Marc André; Nicola Gökbuget; Hervé Tilly; Mats Jerkeman; John Gribben; Andrés Ferreri; Pierre Morel; Stephan Stilgenbauer; Christopher Fox; José Maria Ribera; Sonja Zweegman; Igor Aurer; Csaba Bödör; Birgit Burkhardt; Christian Buske; Maria Dollores Caballero; Elias Campo; Bjoern Chapuy; Andrew Davies; Laurence de Leval; Jeanette Doorduijn; Massimo Federico; Philippe Gaulard; Francesca Gay; Paolo Ghia; Kirsten Grønbæk; Hartmut Goldschmidt; Marie-Jose Kersten; Barbara Kiesewetter; Judith Landman-Parker; Steven le Gouill; Georg Lenz; Sirpa Leppä; Armando Lopez-Guillermo; Elizabeth Macintyre; Maria Victoria Mateos Mantega; Philippe Moreau; Carol Moreno; Bertrand Nadel; Jessica Okosun; Roger Owen; Sarka Pospisilova; Christiane Pott; Tadeusz Robak; Michelle Spina; Kostas Stamatopoulos; Jan Stary; Karin Tarte; Allessandra Tedeschi; Catherine Thieblemont; Ralf Ulrich Trappe; Lorenz H. Trümper; Gilles Salles

doi:https://doi.org/10.1097/HS9.0000000000000726

The EHA Research Roadmap: Malignant Lymphoid Diseases

Martin Dreyling, Marc André, Nicola Gökbuget, Hervé Tilly, Mats Jerkeman, John Gribben, Andrés Ferreri, Pierre Morel, Stephan Stilgenbauer, Christopher Fox, José Maria Ribera, Sonja Zweegman, Igor Aurer, Csaba Bödör, Birgit Burkhardt, Christian Buske, Maria Dollores Caballero, Elias Campo, Bjoern Chapuy, Andrew DaviesLaurence de Leval, Jeanette Doorduijn, Massimo Federico, Philippe Gaulard, Francesca Gay, Paolo Ghia, Kirsten Grønbæk, Hartmut Goldschmidt, Marie-Jose Kersten, Barbara Kiesewetter, Judith Landman-Parker, Steven le Gouill, Georg Lenz, Sirpa Leppä, Armando Lopez-Guillermo, Elizabeth Macintyre, Maria Victoria Mateos Mantega, Philippe Moreau, Carol Moreno, Bertrand Nadel, Jessica Okosun, Roger Owen, Sarka Pospisilova, Christiane Pott, Tadeusz Robak, Michelle Spina, Kostas Stamatopoulos, Jan Stary, Karin Tarte, Allessandra Tedeschi, Catherine Thieblemont, Ralf Ulrich Trappe, Lorenz H. Trümper, Gilles Salles

Research output: Contribution to journal › Review article › Academic › peer-review

3 Citations (Scopus)

Abstract

In 2016, the European Hematology Association (EHA) published the EHA Roadmap for European Hematology Research1 iming to highlight achievements in the diagnostics and treatment of blood disorders and to better inform European policy makers and other stakeholders about the urgent clinical and scientific needs and priorities in the field of hematology. Each section was coordinated by 1 to 2 section editors who were leading international experts in the field. In the 5 years that have followed, advances in the field of hematology have been plentiful. As such, EHA is pleased to present an updated Research Roadmap, now including 11 sections, each of which will be published separately. The updated EHA Research Roadmap identifies the most urgent priorities in hematology research and clinical science, therefore supporting a more informed, focused, and ideally a more funded future for European hematology research. The 11 EHA Research Roadmap sections include Normal Hematopoiesis; Malignant Lymphoid Diseases; Malignant Myeloid Diseases; Anemias and Related Diseases; Platelet Disorders; Blood Coagulation and Hemostatic Disorders; Transfusion Medicine; Infections in Hematology; Hematopoietic Stem Cell Transplantation; CAR-T and Other Cellbased Immune Therapies; and Gene Therapy.

Original language	English
Pages (from-to)	E726
Journal	HemaSphere
Volume	6
Issue number	6
DOIs	https://doi.org/10.1097/HS9.0000000000000726
Publication status	Published - 19 Jun 2022

Access to Document

https://doi.org/10.1097/HS9.0000000000000726

Cite this

Dreyling, M., André, M., Gökbuget, N., Tilly, H., Jerkeman, M., Gribben, J., Ferreri, A., Morel, P., Stilgenbauer, S., Fox, C., Maria Ribera, J., Zweegman, S., Aurer, I., Bödör, C., Burkhardt, B., Buske, C., Dollores Caballero, M., Campo, E., Chapuy, B., ... Salles, G. (2022). The EHA Research Roadmap: Malignant Lymphoid Diseases. HemaSphere, 6(6), E726. https://doi.org/10.1097/HS9.0000000000000726

@article{f8bb49a11e94452c914651984042728a,

title = "The EHA Research Roadmap: Malignant Lymphoid Diseases",

abstract = "In 2016, the European Hematology Association (EHA) published the EHA Roadmap for European Hematology Research1 iming to highlight achievements in the diagnostics and treatment of blood disorders and to better inform European policy makers and other stakeholders about the urgent clinical and scientific needs and priorities in the field of hematology. Each section was coordinated by 1 to 2 section editors who were leading international experts in the field. In the 5 years that have followed, advances in the field of hematology have been plentiful. As such, EHA is pleased to present an updated Research Roadmap, now including 11 sections, each of which will be published separately. The updated EHA Research Roadmap identifies the most urgent priorities in hematology research and clinical science, therefore supporting a more informed, focused, and ideally a more funded future for European hematology research. The 11 EHA Research Roadmap sections include Normal Hematopoiesis; Malignant Lymphoid Diseases; Malignant Myeloid Diseases; Anemias and Related Diseases; Platelet Disorders; Blood Coagulation and Hemostatic Disorders; Transfusion Medicine; Infections in Hematology; Hematopoietic Stem Cell Transplantation; CAR-T and Other Cellbased Immune Therapies; and Gene Therapy.",

author = "Martin Dreyling and Marc Andr{\'e} and Nicola G{\"o}kbuget and Herv{\'e} Tilly and Mats Jerkeman and John Gribben and Andr{\'e}s Ferreri and Pierre Morel and Stephan Stilgenbauer and Christopher Fox and {Maria Ribera}, Jos{\'e} and Sonja Zweegman and Igor Aurer and Csaba B{\"o}d{\"o}r and Birgit Burkhardt and Christian Buske and {Dollores Caballero}, Maria and Elias Campo and Bjoern Chapuy and Andrew Davies and {de Leval}, Laurence and Jeanette Doorduijn and Massimo Federico and Philippe Gaulard and Francesca Gay and Paolo Ghia and Kirsten Gr{\o}nb{\ae}k and Hartmut Goldschmidt and Marie-Jose Kersten and Barbara Kiesewetter and Judith Landman-Parker and {le Gouill}, Steven and Georg Lenz and Sirpa Lepp{\"a} and Armando Lopez-Guillermo and Elizabeth Macintyre and Mantega, {Maria Victoria Mateos} and Philippe Moreau and Carol Moreno and Bertrand Nadel and Jessica Okosun and Roger Owen and Sarka Pospisilova and Christiane Pott and Tadeusz Robak and Michelle Spina and Kostas Stamatopoulos and Jan Stary and Karin Tarte and Allessandra Tedeschi and Catherine Thieblemont and Trappe, {Ralf Ulrich} and Tr{\"u}mper, {Lorenz H.} and Gilles Salles",

note = "Funding Information: MD receives research support from AbbVie, Bayer, Celgene, Janssen, and Roche; he is a HemaSphere editor; he receives speakers honoraria from Amgen, Astra Zeneca, Bayer, Celgene, Gilead, Janssen, and Roche; and he belongs to the Scientific Advisory Board of Astra Zeneca, Bayer, BMS/Celgene, Beigene, Genmab, Gilead, Incyte, Janssen, Novartis, and Roche. MA is a consultant for Takeda, Bristol-Myers-Squibb, Karyopharm, Gilead, Incyte and receives research support from Roche, Johnson & Johnson, and Takeda. NG receives research support from Amgen, Pfizer, Novartis,Shire/Servier, Jazz Pharmaceuticals, Incyte; she receives honoraria from Amgen, Celgene, Gilead, Novartis, Pfizer, Jazz Pharmaceuticals, Incyte. HT is a member of the advisory board for Roche, Celgene, Incyte. JG provides consultation for Abbvie, Astra Zeneca, BMS, Gilead, Janssen, Morphosys, TG Therapeutics; he receives research support from Astra Zeneca, Janssen and honoraria from Abbvie, BMS, Gilead, Janssen. AF is a member of advisory board for Gilead, Novartis, Roche, Juno, PletixaPharm; he receives research support from BMS, Beigene, Pharmacyclics, Hutchison Medipharma, Amgen, Genmab, ADC Therapeutics, Roche, Gilead, Novartis, Pfizer; he receives honoraria from Adienne and Gilead. SS receives consulting fees, research support and honoraria from AbbVie, Amgen, AstraZeneca, BeiGene, BMS, Celgene, Gilead, GSK, Hoffmann-La Roche, Janssen, Novartis, Sunesis. CF receives consulting fees from AbbVie, AstraZeneca, Atarabio,BMS/Celgene, Gilead/Kite, Janssen, Incyte, Roche, Takeda, BeiGene; he receives research support from BeiGene; he receives honoraria from Takeda, Incyte, Roche, Janssen. JMR receives research support from Amgen, Pfizer, Takeda, Incyte, Servier, Novartis; he receives honoraria from Amgen, Pfizer, Incyte, Servier, Novartis. SZ receives research support from Janssen and Takeda. IA receives financial support from Roche, Janssen, Novartis/Sandoz, Takeda, Amgen, Eusapharma, AbbVie, Oktalpharma/Celtrion, Sanofi Genzyme, Teva/Pliva, Swixx/BMS. CB receives payments for lectures from Abbvie, Jannsen, Pfizer, Roche. BB is member of the advisory board, steering committee and expert for AbbVie, Miletyi, Novartis, Roche. CB received honoraria from Roche, Janssen, BeiGene, Gilead, AbbVie, Celltrion, Pfizer, Novartis, Regeneron, Incyte; he received research funds from Roche, Janssen, AbbVie, MSD, Celltrion, Pfizer, Amgen. EC receives consulting fees from Illumina and AbbVie; he receives honoraria from EUSA Pharma, AstraZeneca; he is author on a patent licensed to NanoString Technologies. BC receives honoraria from BMS, Gilead, Astra Zeneca. AD receives consulting fees from Roche, Acerta/AstraZeneca; he receives research support from Roche, Celgene/BMS, Kite/Gilead, Incyte; he is advisory board member in Roche, Incyte, AstraZeneca, Genmab, Abbvie. FG receives consulting fees from Janssen, Amgen BMS/Celgene, Sanofi, Pfizer, Oncopeptides, GSK, Roche, AbbVie; she receives honoraria from Janssen, Amgen, BMS/Celgene, Sanofi, GSK, AbbVie. PG receives consulting fees from AbbVie, AstraZeneca, ArQule/MSD, BeiGene, Celgene/Juno/BMS, Janssen, Lilly, MEI, Roche, Sanofi; he receives research support from AbbVie, AstraZeneca, Janssen, Sunesis; he is an editor for HemaSphere. HG receives consulting fees from Amgen, BMS, Celgene, Chugai, Janssen, Sanofi; he receives research support from Amgen, BMS, Celgene, Chugai, Janssen, Incyte, Molecular Partners, Merck Sharp and Dohme (MSD), Sanofi, Mundipharma GmbH, Takeda, Novartis; he is an advisory board member for Adaptive Biotechnology, Amgen, BMS, Celgene, Janssen, Sanofi, Takeda; he receives honoraria for Amgen, BMS, Celgene, Chugai, GlaxoSmithKline (GSK), Janssen, Novartis, Sanofi. MJ receives research support from Abbvie, AstraZeneca, Janssen, Roche; he receives honoraria from Janssen, Abbvie, Genmab, Incyte. MJK received research support from Gilead; she receives honoraria from Kite/Gilead, BMS/Celgene, Novartis, Miltenyi Biotec, Roche, Takeda. BK receives honoraria for lectures from AAA, Ipsen, Novartis, MSD, Lilly and is an advisory board member for Ipsen. GL receives consulting fees from Roche, Gilead, Janssen, BMS, Novartis, AstraZeneca, Abbvie, Incyte, MorphoSys, Genmab, Karyopharm, Constellation; he receives research support from Roche, Gilead, Janssen, Bayer, AstraZeneca, MorphoSys; he receives honoraria from Roche, Gilead, Janssen, BMS, Novarts, AstraZeneca, Abbvie, Incyte, MorphoSys. SL receives consulting fees from Genmab, Incyte, Gilead, Orion, CHO Pharma USA, Novartis, Roche; she receives honoraria from Novartis, GILEAD, Incyte. ALG receives consulting fees from Roche, Gilead/Kite, Celgene, Novartis, Astra Zeneca, Abbie, Morphosis, Takeda; he receives research support from Roche, Gilead/Kite, Celgene; he receives honoraria from Roche, Gilead/Kite. MVMM receives honoraria derived from lectures and participation in advisory boards from Janssen, Celgene, Takeda, Amgen, GSK, Abbvie, Pfizer, Regeneron, Adaptive, Roche, Seattle Genentech. PM receives honoraria and is an advisory board member in Celgene/BMS, Janssen, Amgen, Sanofi, AbbVie. CM receives consulting fees from Abbvie, Janssen, AstraZeneca, Beigene; she receives research support from Abbvie and Janssen. JO receives research support from Gilead Science and BeiGene; she receives honoraria from Gilead Science. RO receives honoraria and is an advisory board member in BeiGene and Janssen. TR receives consulting fees from BeiGene, AstraZeneca, Janssen, Abbvie; he receives research support from BeiGene, AstraZeneza, Janssen, Octapharma, Moderna, GSK, Abbvie. KS receives research support from Janssen, Abbvie, Roche, AstraZeneca; he receives honoraria from Janssen, Abbvie, Roche, AstraZeneca. AT receives honoraria and is an advisory board member for Janssen Spa, Beigene, AstraZeneca, AbbVie. RUT receives payments for consultation and attending advisory board meetings from Atara. All the other authors have no conflicts of interest to disclose. Publisher Copyright: {\textcopyright} 2022 Wolters Kluwer Health. All rights reserved.",

year = "2022",

month = jun,

day = "19",

doi = "https://doi.org/10.1097/HS9.0000000000000726",

language = "English",

volume = "6",

pages = "E726",

journal = "HemaSphere",

issn = "2572-9241",

publisher = "Wolters Kluwer Health",

number = "6",

}

Dreyling, M, André, M, Gökbuget, N, Tilly, H, Jerkeman, M, Gribben, J, Ferreri, A, Morel, P, Stilgenbauer, S, Fox, C, Maria Ribera, J, Zweegman, S, Aurer, I, Bödör, C, Burkhardt, B, Buske, C, Dollores Caballero, M, Campo, E, Chapuy, B, Davies, A, de Leval, L, Doorduijn, J, Federico, M, Gaulard, P, Gay, F, Ghia, P, Grønbæk, K, Goldschmidt, H, Kersten, M-J, Kiesewetter, B, Landman-Parker, J, le Gouill, S, Lenz, G, Leppä, S, Lopez-Guillermo, A, Macintyre, E, Mantega, MVM, Moreau, P, Moreno, C, Nadel, B, Okosun, J, Owen, R, Pospisilova, S, Pott, C, Robak, T, Spina, M, Stamatopoulos, K, Stary, J, Tarte, K, Tedeschi, A, Thieblemont, C, Trappe, RU, Trümper, LH & Salles, G 2022, 'The EHA Research Roadmap: Malignant Lymphoid Diseases', HemaSphere, vol. 6, no. 6, pp. E726. https://doi.org/10.1097/HS9.0000000000000726

TY - JOUR

T1 - The EHA Research Roadmap

T2 - Malignant Lymphoid Diseases

AU - Dreyling, Martin

AU - André, Marc

AU - Gökbuget, Nicola

AU - Tilly, Hervé

AU - Jerkeman, Mats

AU - Gribben, John

AU - Ferreri, Andrés

AU - Morel, Pierre

AU - Stilgenbauer, Stephan

AU - Fox, Christopher

AU - Maria Ribera, José

AU - Zweegman, Sonja

AU - Aurer, Igor

AU - Bödör, Csaba

AU - Burkhardt, Birgit

AU - Buske, Christian

AU - Dollores Caballero, Maria

AU - Campo, Elias

AU - Chapuy, Bjoern

AU - Davies, Andrew

AU - de Leval, Laurence

AU - Doorduijn, Jeanette

AU - Federico, Massimo

AU - Gaulard, Philippe

AU - Gay, Francesca

AU - Ghia, Paolo

AU - Grønbæk, Kirsten

AU - Goldschmidt, Hartmut

AU - Kersten, Marie-Jose

AU - Kiesewetter, Barbara

AU - Landman-Parker, Judith

AU - le Gouill, Steven

AU - Lenz, Georg

AU - Leppä, Sirpa

AU - Lopez-Guillermo, Armando

AU - Macintyre, Elizabeth

AU - Mantega, Maria Victoria Mateos

AU - Moreau, Philippe

AU - Moreno, Carol

AU - Nadel, Bertrand

AU - Okosun, Jessica

AU - Owen, Roger

AU - Pospisilova, Sarka

AU - Pott, Christiane

AU - Robak, Tadeusz

AU - Spina, Michelle

AU - Stamatopoulos, Kostas

AU - Stary, Jan

AU - Tarte, Karin

AU - Tedeschi, Allessandra

AU - Thieblemont, Catherine

AU - Trappe, Ralf Ulrich

AU - Trümper, Lorenz H.

AU - Salles, Gilles

N1 - Funding Information: MD receives research support from AbbVie, Bayer, Celgene, Janssen, and Roche; he is a HemaSphere editor; he receives speakers honoraria from Amgen, Astra Zeneca, Bayer, Celgene, Gilead, Janssen, and Roche; and he belongs to the Scientific Advisory Board of Astra Zeneca, Bayer, BMS/Celgene, Beigene, Genmab, Gilead, Incyte, Janssen, Novartis, and Roche. MA is a consultant for Takeda, Bristol-Myers-Squibb, Karyopharm, Gilead, Incyte and receives research support from Roche, Johnson & Johnson, and Takeda. NG receives research support from Amgen, Pfizer, Novartis,Shire/Servier, Jazz Pharmaceuticals, Incyte; she receives honoraria from Amgen, Celgene, Gilead, Novartis, Pfizer, Jazz Pharmaceuticals, Incyte. HT is a member of the advisory board for Roche, Celgene, Incyte. JG provides consultation for Abbvie, Astra Zeneca, BMS, Gilead, Janssen, Morphosys, TG Therapeutics; he receives research support from Astra Zeneca, Janssen and honoraria from Abbvie, BMS, Gilead, Janssen. AF is a member of advisory board for Gilead, Novartis, Roche, Juno, PletixaPharm; he receives research support from BMS, Beigene, Pharmacyclics, Hutchison Medipharma, Amgen, Genmab, ADC Therapeutics, Roche, Gilead, Novartis, Pfizer; he receives honoraria from Adienne and Gilead. SS receives consulting fees, research support and honoraria from AbbVie, Amgen, AstraZeneca, BeiGene, BMS, Celgene, Gilead, GSK, Hoffmann-La Roche, Janssen, Novartis, Sunesis. CF receives consulting fees from AbbVie, AstraZeneca, Atarabio,BMS/Celgene, Gilead/Kite, Janssen, Incyte, Roche, Takeda, BeiGene; he receives research support from BeiGene; he receives honoraria from Takeda, Incyte, Roche, Janssen. JMR receives research support from Amgen, Pfizer, Takeda, Incyte, Servier, Novartis; he receives honoraria from Amgen, Pfizer, Incyte, Servier, Novartis. SZ receives research support from Janssen and Takeda. IA receives financial support from Roche, Janssen, Novartis/Sandoz, Takeda, Amgen, Eusapharma, AbbVie, Oktalpharma/Celtrion, Sanofi Genzyme, Teva/Pliva, Swixx/BMS. CB receives payments for lectures from Abbvie, Jannsen, Pfizer, Roche. BB is member of the advisory board, steering committee and expert for AbbVie, Miletyi, Novartis, Roche. CB received honoraria from Roche, Janssen, BeiGene, Gilead, AbbVie, Celltrion, Pfizer, Novartis, Regeneron, Incyte; he received research funds from Roche, Janssen, AbbVie, MSD, Celltrion, Pfizer, Amgen. EC receives consulting fees from Illumina and AbbVie; he receives honoraria from EUSA Pharma, AstraZeneca; he is author on a patent licensed to NanoString Technologies. BC receives honoraria from BMS, Gilead, Astra Zeneca. AD receives consulting fees from Roche, Acerta/AstraZeneca; he receives research support from Roche, Celgene/BMS, Kite/Gilead, Incyte; he is advisory board member in Roche, Incyte, AstraZeneca, Genmab, Abbvie. FG receives consulting fees from Janssen, Amgen BMS/Celgene, Sanofi, Pfizer, Oncopeptides, GSK, Roche, AbbVie; she receives honoraria from Janssen, Amgen, BMS/Celgene, Sanofi, GSK, AbbVie. PG receives consulting fees from AbbVie, AstraZeneca, ArQule/MSD, BeiGene, Celgene/Juno/BMS, Janssen, Lilly, MEI, Roche, Sanofi; he receives research support from AbbVie, AstraZeneca, Janssen, Sunesis; he is an editor for HemaSphere. HG receives consulting fees from Amgen, BMS, Celgene, Chugai, Janssen, Sanofi; he receives research support from Amgen, BMS, Celgene, Chugai, Janssen, Incyte, Molecular Partners, Merck Sharp and Dohme (MSD), Sanofi, Mundipharma GmbH, Takeda, Novartis; he is an advisory board member for Adaptive Biotechnology, Amgen, BMS, Celgene, Janssen, Sanofi, Takeda; he receives honoraria for Amgen, BMS, Celgene, Chugai, GlaxoSmithKline (GSK), Janssen, Novartis, Sanofi. MJ receives research support from Abbvie, AstraZeneca, Janssen, Roche; he receives honoraria from Janssen, Abbvie, Genmab, Incyte. MJK received research support from Gilead; she receives honoraria from Kite/Gilead, BMS/Celgene, Novartis, Miltenyi Biotec, Roche, Takeda. BK receives honoraria for lectures from AAA, Ipsen, Novartis, MSD, Lilly and is an advisory board member for Ipsen. GL receives consulting fees from Roche, Gilead, Janssen, BMS, Novartis, AstraZeneca, Abbvie, Incyte, MorphoSys, Genmab, Karyopharm, Constellation; he receives research support from Roche, Gilead, Janssen, Bayer, AstraZeneca, MorphoSys; he receives honoraria from Roche, Gilead, Janssen, BMS, Novarts, AstraZeneca, Abbvie, Incyte, MorphoSys. SL receives consulting fees from Genmab, Incyte, Gilead, Orion, CHO Pharma USA, Novartis, Roche; she receives honoraria from Novartis, GILEAD, Incyte. ALG receives consulting fees from Roche, Gilead/Kite, Celgene, Novartis, Astra Zeneca, Abbie, Morphosis, Takeda; he receives research support from Roche, Gilead/Kite, Celgene; he receives honoraria from Roche, Gilead/Kite. MVMM receives honoraria derived from lectures and participation in advisory boards from Janssen, Celgene, Takeda, Amgen, GSK, Abbvie, Pfizer, Regeneron, Adaptive, Roche, Seattle Genentech. PM receives honoraria and is an advisory board member in Celgene/BMS, Janssen, Amgen, Sanofi, AbbVie. CM receives consulting fees from Abbvie, Janssen, AstraZeneca, Beigene; she receives research support from Abbvie and Janssen. JO receives research support from Gilead Science and BeiGene; she receives honoraria from Gilead Science. RO receives honoraria and is an advisory board member in BeiGene and Janssen. TR receives consulting fees from BeiGene, AstraZeneca, Janssen, Abbvie; he receives research support from BeiGene, AstraZeneza, Janssen, Octapharma, Moderna, GSK, Abbvie. KS receives research support from Janssen, Abbvie, Roche, AstraZeneca; he receives honoraria from Janssen, Abbvie, Roche, AstraZeneca. AT receives honoraria and is an advisory board member for Janssen Spa, Beigene, AstraZeneca, AbbVie. RUT receives payments for consultation and attending advisory board meetings from Atara. All the other authors have no conflicts of interest to disclose. Publisher Copyright: © 2022 Wolters Kluwer Health. All rights reserved.

PY - 2022/6/19

Y1 - 2022/6/19

N2 - In 2016, the European Hematology Association (EHA) published the EHA Roadmap for European Hematology Research1 iming to highlight achievements in the diagnostics and treatment of blood disorders and to better inform European policy makers and other stakeholders about the urgent clinical and scientific needs and priorities in the field of hematology. Each section was coordinated by 1 to 2 section editors who were leading international experts in the field. In the 5 years that have followed, advances in the field of hematology have been plentiful. As such, EHA is pleased to present an updated Research Roadmap, now including 11 sections, each of which will be published separately. The updated EHA Research Roadmap identifies the most urgent priorities in hematology research and clinical science, therefore supporting a more informed, focused, and ideally a more funded future for European hematology research. The 11 EHA Research Roadmap sections include Normal Hematopoiesis; Malignant Lymphoid Diseases; Malignant Myeloid Diseases; Anemias and Related Diseases; Platelet Disorders; Blood Coagulation and Hemostatic Disorders; Transfusion Medicine; Infections in Hematology; Hematopoietic Stem Cell Transplantation; CAR-T and Other Cellbased Immune Therapies; and Gene Therapy.

AB - In 2016, the European Hematology Association (EHA) published the EHA Roadmap for European Hematology Research1 iming to highlight achievements in the diagnostics and treatment of blood disorders and to better inform European policy makers and other stakeholders about the urgent clinical and scientific needs and priorities in the field of hematology. Each section was coordinated by 1 to 2 section editors who were leading international experts in the field. In the 5 years that have followed, advances in the field of hematology have been plentiful. As such, EHA is pleased to present an updated Research Roadmap, now including 11 sections, each of which will be published separately. The updated EHA Research Roadmap identifies the most urgent priorities in hematology research and clinical science, therefore supporting a more informed, focused, and ideally a more funded future for European hematology research. The 11 EHA Research Roadmap sections include Normal Hematopoiesis; Malignant Lymphoid Diseases; Malignant Myeloid Diseases; Anemias and Related Diseases; Platelet Disorders; Blood Coagulation and Hemostatic Disorders; Transfusion Medicine; Infections in Hematology; Hematopoietic Stem Cell Transplantation; CAR-T and Other Cellbased Immune Therapies; and Gene Therapy.

UR - http://www.scopus.com/inward/record.url?scp=85131642961&partnerID=8YFLogxK

U2 - https://doi.org/10.1097/HS9.0000000000000726

DO - https://doi.org/10.1097/HS9.0000000000000726

M3 - Review article

C2 - 35620592

SN - 2572-9241

VL - 6

SP - E726

JO - HemaSphere

JF - HemaSphere

IS - 6

ER -

The EHA Research Roadmap: Malignant Lymphoid Diseases

Abstract

Access to Document

Other files and links

Cite this